NASDAQ:BBIO

BridgeBio Pharma News Headlines

$62.12
-1.81 (-2.83 %)
(As of 06/14/2021 01:52 PM ET)
Add
Compare
Today's Range
$61.90
$64.14
50-Day Range
$46.47
$63.93
52-Week Range
$26.17
$73.50
Volume28,017 shs
Average Volume918,614 shs
Market Capitalization$9.27 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.77

BridgeBio Pharma (NASDAQ BBIO) News Headlines Today

SourceHeadline
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by UBS GroupBridgeBio Pharma (NASDAQ:BBIO) Now Covered by UBS Group
marketbeat.com - May 26 at 8:34 AM
BridgeBio Stock Flashes Healthy 83 RS RatingBridgeBio Stock Flashes Healthy 83 RS Rating
finance.yahoo.com - June 2 at 7:09 PM
FDA Approves BridgeBio Pharmas FGFR2 Inhibitor for Bile Duct CancerFDA Approves BridgeBio Pharma's FGFR2 Inhibitor for Bile Duct Cancer
finance.yahoo.com - June 1 at 1:53 PM
BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1
finance.yahoo.com - June 1 at 8:52 AM
Faron Pharma Share ChatFaron Pharma Share Chat
lse.co.uk - May 30 at 7:06 PM
BridgeBio Pharmas Affiliate QED...BridgeBio Pharma's Affiliate QED...
benzinga.com - May 28 at 7:01 PM
BridgeBios lean focus on genetic drivers scores 2nd drug approval in 3 monthsBridgeBio's lean focus on genetic drivers scores 2nd drug approval in 3 months
bizjournals.com - May 28 at 7:01 PM
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with CholangiocarcinomaBridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
finance.yahoo.com - May 28 at 7:01 PM
BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated by Analysts at UBS GroupBridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated by Analysts at UBS Group
americanbankingnews.com - May 26 at 9:56 AM
First Week of July 16th Options Trading For BridgeBio Pharma (BBIO)First Week of July 16th Options Trading For BridgeBio Pharma (BBIO)
nasdaq.com - May 21 at 1:56 PM
BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at UBS GroupBridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at UBS Group
americanbankingnews.com - May 20 at 5:10 PM
BridgeBio Gets FDA Fast Track Designation For Gene Therapy For Congenital Adrenal HyperplasiaBridgeBio Gets FDA Fast Track Designation For Gene Therapy For Congenital Adrenal Hyperplasia
nasdaq.com - May 14 at 10:58 AM
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal HyperplasiaBridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia
finance.yahoo.com - May 14 at 10:58 AM
BridgeBio Pharma Breaks Below 200-Day Moving Average - Notable for BBIOBridgeBio Pharma Breaks Below 200-Day Moving Average - Notable for BBIO
nasdaq.com - May 6 at 6:41 PM
BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue EstimatesBridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 6 at 1:41 PM
BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business UpdateBridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update
finance.yahoo.com - May 6 at 8:41 AM
BridgeBio Pharma Stock Forecast: A Long-Term Buy Or SellBridgeBio Pharma Stock Forecast: A Long-Term Buy Or Sell
seekingalpha.com - May 5 at 5:39 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BridgeBio Pharma, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BridgeBio Pharma, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - May 3 at 1:24 PM
Is BridgeBio Pharma Inc. (BBIO) A Smart Long-Term Buy?Is BridgeBio Pharma Inc. (BBIO) A Smart Long-Term Buy?
finance.yahoo.com - April 30 at 2:41 PM
Is BBIO Stock A Buy or Sell?Is BBIO Stock A Buy or Sell?
finance.yahoo.com - April 24 at 2:13 PM
First Week of June 18th Options Trading For BridgeBio Pharma (BBIO)First Week of June 18th Options Trading For BridgeBio Pharma (BBIO)
nasdaq.com - April 16 at 5:44 PM
BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven CancersBridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers
finance.yahoo.com - April 13 at 10:02 AM
BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven ConditionsBridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions
finance.yahoo.com - April 13 at 10:02 AM
BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics ResearchBridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research
markets.businessinsider.com - April 13 at 7:41 AM
BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and CancersBridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers
markets.businessinsider.com - April 13 at 7:41 AM
Could The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Ownership Structure Tell Us Something Useful?Could The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Ownership Structure Tell Us Something Useful?
nasdaq.com - April 8 at 6:52 PM
First Week of BBIO April 16th Options TradingFirst Week of BBIO April 16th Options Trading
nasdaq.com - April 5 at 2:13 PM
BridgeBio Locks $2B Infigratinib Global Partnership For Oncology IndicationsBridgeBio Locks $2B Infigratinib Global Partnership For Oncology Indications
finance.yahoo.com - March 31 at 6:44 PM
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in OncologyBridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
finance.yahoo.com - March 31 at 8:42 AM
Interesting BBIO Put And Call Options For May 21stInteresting BBIO Put And Call Options For May 21st
nasdaq.com - March 22 at 1:39 PM
BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual MeetingBridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting
finance.yahoo.com - March 20 at 1:43 PM
First Week of BBIO November 19th Options TradingFirst Week of BBIO November 19th Options Trading
nasdaq.com - March 19 at 7:11 PM
First Week of BBIO August 20th Options TradingFirst Week of BBIO August 20th Options Trading
nasdaq.com - March 18 at 2:45 PM
BridgeBio : FDA Approves NULIBRY To Reduce Risk Of Mortality In Patients With MoCD Type ABridgeBio : FDA Approves NULIBRY To Reduce Risk Of Mortality In Patients With MoCD Type A
nasdaq.com - March 1 at 7:22 PM
BridgeBio Jumps 6% Pre-Market On FDA Approval For NulibryBridgeBio Jumps 6% Pre-Market On FDA Approval For Nulibry
finance.yahoo.com - March 1 at 2:21 PM
BridgeBio Pharma Gets First FDA-Approval For Rare Genetic Metabolic DisorderBridgeBio Pharma Gets First FDA-Approval For Rare Genetic Metabolic Disorder
finance.yahoo.com - March 1 at 9:17 AM
BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type ABridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
finance.yahoo.com - February 28 at 8:44 AM
Tackling deadly newborn disease, BridgeBio affiliate wins FDA drug approvalTackling deadly newborn disease, BridgeBio affiliate wins FDA drug approval
bizjournals.com - February 26 at 6:42 PM
Is a Surprise Coming for BridgeBio Pharma (BBIO) This Earnings Season?Is a Surprise Coming for BridgeBio Pharma (BBIO) This Earnings Season?
finance.yahoo.com - February 26 at 1:41 PM
BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue EstimatesBridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates
nasdaq.com - February 25 at 2:55 PM
BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual MeetingBridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting
finance.yahoo.com - February 24 at 6:22 PM
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
msn.com - February 22 at 1:44 PM
BridgeBio Pharmas BBP-418 Muscular Dystrophy Study Moves Forward With Patient DosingBridgeBio Pharma's BBP-418 Muscular Dystrophy Study Moves Forward With Patient Dosing
finance.yahoo.com - February 19 at 7:10 PM
BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
finance.yahoo.com - February 19 at 9:09 AM
Is BridgeBio Pharma (BBIO) Stock a Buy For 2021?Is BridgeBio Pharma (BBIO) Stock a Buy For 2021?
finance.yahoo.com - February 17 at 2:44 PM
Why BridgeBio Pharmas Stock is Up During Todays SessionWhy BridgeBio Pharma's Stock is Up During Today's Session
msn.com - February 12 at 2:12 PM
BridgeBio Pharma, Inc. Announces Pricing of Secondary Offering of Common StockBridgeBio Pharma, Inc. Announces Pricing of Secondary Offering of Common Stock
finance.yahoo.com - February 12 at 9:11 AM
BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common StockBridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common Stock
finance.yahoo.com - February 11 at 5:21 PM
BridgeBio Pharma (NASDAQ:BBIO) Shareholders Have Enjoyed A 82% Share Price GainBridgeBio Pharma (NASDAQ:BBIO) Shareholders Have Enjoyed A 82% Share Price Gain
finance.yahoo.com - February 5 at 8:24 AM
BridgeBio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of BBP-681 for Venous, Lymphatic, and Venolymphatic MalformationsBridgeBio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of BBP-681 for Venous, Lymphatic, and Venolymphatic Malformations
finance.yahoo.com - February 2 at 9:16 AM
BridgeBios Eidos Merger And Its RationaleBridgeBio's Eidos Merger And Its Rationale
seekingalpha.com - January 31 at 6:10 AM
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.